GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company focused on developing human vaccines and cancer immunotherapies, announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the upcoming 3rd Annual ROTH Healthcare Opportunities Conference. The event is scheduled for October 9, 2024, in New York, NY.
The panel, titled 'Innovative Therapies for Solid Tumors,' will feature Dodd's insights at 12:30 pm ET. This participation underscores GeoVax's growing presence in the oncology field, particularly in developing novel treatments for solid tumors. The company's involvement in such a high-profile conference may signal important developments in their cancer therapy pipeline, potentially offering new hope for patients with difficult-to-treat solid tumors.
GeoVax's diverse portfolio includes GEO-CM04S1, a next-generation COVID-19 vaccine currently in multiple Phase 2 clinical trials. The company recently secured a BARDA-funded contract for a 10,000-participant Phase 2b trial to evaluate this vaccine's efficacy against an approved COVID-19 vaccine. This development could have significant implications for public health strategies, especially for immunocompromised patients and those seeking more durable protection against COVID-19.
In the oncology sector, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, currently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The progress of this therapy could potentially revolutionize treatment options for patients with these challenging cancers.
The company's participation in the ROTH conference not only provides a platform to showcase these advancements but also offers an opportunity for potential collaborations and investments. As the biotechnology sector continues to evolve rapidly, GeoVax's innovative approaches in both infectious diseases and oncology position it as a company to watch in the coming years.
